methylprednisolone oral / Generic mfg. - LARVOL DELTA

EMPOWER-2: An Evaluation of the Safety and Efficacy of TSND-201 for the Treatment of PTSD (clinicaltrials.gov) - P3 | N=300 | Recruiting | Sponsor: Transcend Therapeutics

New P3 trial • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Case Report: Probable toripalimab-associated ocular myasthenia gravis-like presentation after chemoimmunotherapy. (PubMed, Front Neurol) - "We report a 60-year-old woman with triple-negative right breast cancer who developed bilateral ptosis and mild limitation of horizontal eye movements approximately 2 weeks after receiving nab-paclitaxel, carboplatin, and toripalimab...Toripalimab was discontinued, and oral methylprednisolone 20 mg once daily was administered for 6 days from January 17 to January 22, 2026, beginning the day after discharge...The significance of RYR-IgG and Titin-IgG positivity in this patient remains uncertain because the assay platform and laboratory cut-offs were unavailable. Their detection should not be regarded as confirmation of ocular myasthenia gravis."

Journal • Breast Cancer • CNS Disorders • Dyslipidemia • Immunology • Myasthenia Gravis • Myositis • Oncology • Solid Tumor • Triple Negative Breast Cancer • MB • TTN

A Phase 1 Study of Ruxolitinib, Lenalidomide and Steroids for Patients with Relapsed/Refractory Multiple Myeloma. (PubMed, Clin Cancer Res) - "This study provides the basis for studying the addition of JAK inhibitors to improve the efficacy of immunomodulatory agents with steroids for treating myeloma patients but perhaps can also be expanded for treating other cancer patients that are refractory to this class of drugs."

Clinical • Journal • P1 data • Hematological Disorders • Hematological Malignancies • Immune Modulation • Infectious Disease • Inflammation • Multiple Myeloma • Oncology • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

A REAL-WORLD STUDY OF INOTUZUMAB OZOGAMICIN COMBINED WITH VENETOCLAX AS FRONTLINE THERAPY FOR NEWLY-DIAGNOSED PH-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITH SEVERE COMORBIDITY (EHA 2026) - P | "1 cycle of induction cycle consists of INO 1mg at day1, day8, day15; VEN 100mg at day1, 200mg at day2, 400mg from day3 to day21 orally; Methylprednisolone 1mg/kg for 2 weeks followed by a 2-weeks taper. Table 1. Baseline characteristics and responses of all patients"

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Hepatology • Neutropenia • Thrombocytopenia • CD22

Combined in-office endoscopic debridement and supine head-hanging budesonide instillation for postoperative difficult-to-treat chronic rhinosinusitis with nasal polyps: a retrospective cohort study. (PubMed, Front Allergy) - "Fifty-two patients received the intensified strategy, and 50 received conventional budesonide nasal spray; both groups received the same 7-day oral methylprednisolone course...The 12-week endpoint reflects early recorded epithelialization and does not establish durable disease control or recurrence prevention. Prospective component-controlled or factorial studies with follow-up of at least 12 months are needed."

Journal • Retrospective data • Allergic Rhinitis • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis

Alkyl-Chain Extension and Terminal Amine Substitution Shape Cardiotoxic Profiles of Methylenedioxy Cathinones in Zebrafish Embryos. (PubMed, Pharmaceuticals (Basel)) - "This study aimed to compare the cardiotoxic and neurobehavioral profiles of methylone, butylone, pentylone and their N,N-dimethyl analogues, and to determine how alkyl-chain extension and terminal amine substitution shape functional toxicity... Alkyl-chain extension and terminal amine substitution shaped cardiac and neurobehavioral toxicity in a structure-dependent manner. The zebrafish workflow provides a structure-oriented framework for prioritizing emerging methylenedioxy cathinones with comparatively higher functional cardiac liability."

Journal • Cardiovascular

Microbial-Metabolite Signatures Are Associated With Glucocorticoid Responsiveness in Chronic Rhinosinusitis With Nasal Polyps. (PubMed, Int Forum Allergy Rhinol) - "Gut microbiome-plasma metabolomic signatures capture the systemic immunometabolic context of GC therapy and are linked to GC responsiveness in CRSwNP, explaining interindividual treatment efficacy differences."

Journal • Chronic Rhinosinusitis With Nasal Polyps • Immunology • Inflammation • Nasal Polyps • Otorhinolaryngology • Respiratory Diseases • Sinusitis • IL6

Diagnosis and treatment of extranodal Rosai-Dorfman disease in nasal skull base: a report of 5 cases (PubMed, Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi) - "Five patients received oral methylprednisolone after surgery...Endoscopic surgical resection of localized nasal skull base RDD has shown favorable therapeutic outcomes, suggesting the importance of achieving maximal safe resection. The specific regimen of postoperative adjuvant steroid therapy still requires further investigation."

Journal • Retrospective data • Oncology • Otorhinolaryngology • Pain • Rare Diseases

Oral Statins and Protection From Hearing Loss (clinicaltrials.gov) - P4 | N=3 | Terminated | Sponsor: Northwestern University | N=100 ➔ 3 | Recruiting ➔ Terminated; Insufficient funding

Enrollment change • Trial termination • Otorhinolaryngology

Dose-dependent protective effects of punicalagin on steroid-induced osteonecrosis in a rat model. (PubMed, Jt Dis Relat Surg) - "Punicalagin may exert dose-dependent protective effects against SONFH in rats, primarily associated with reduced apoptotic activity and partial preservation of bone microarchitecture. While systemic oxidative stress markers show numerical improvements, the marked reduction in osteocyte apoptosis and necrotic incidence suggests that PUN represents a promising adjunctive strategy for mitigating steroid-related bone injury."

Journal • Preclinical • CASP3 • CAT

Case Report: Bullous erythema multiforme induced by omalizumab. (PubMed, Front Med (Lausanne)) - "Initial treatment with methylprednisolone combined with intravenous immunoglobulin (IVIG) was ineffective. The condition was successfully controlled after increasing the dose of methylprednisolone and adding oral upadacitinib. This case suggests that omalizumab may induce BEM, and combination therapy with high-dose glucocorticoids and JAK inhibitors may be an effective strategy for refractory cases. Clinicians should be alert to such rare adverse reactions when using omalizumab."

Journal • Allergic Rhinitis • Asthma • Chronic Spontaneous Urticaria • Conjunctivitis • Dermatology • Fatigue • Immunology • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • Pulmonary Disease • Respiratory Diseases • Urticaria

Post-inflammatory Isolated Bilateral Palatal Palsy Following Enteric Fever: A Report of a Rare Pediatric Case. (PubMed, Cureus) - "The child was commenced on oral methylprednisolone therapy...Bilateral palatal palsy is exceptionally rare, with only a few cases documented to date. The rarity of bilateral involvement makes the present case a unique clinical observation. Despite its rarity, early recognition is essential to avoid unnecessary investigations and to ensure timely treatment and recovery."

Journal • CNS Disorders • Gastrointestinal Disorder • Infectious Disease • Influenza • Otorhinolaryngology • Pain • Pediatrics • Respiratory Diseases • Varicella Zoster

Tolosa-Hunt Syndrome With Highly Elevated Interleukin-6 Levels. (PubMed, Cureus) - "Both episodes resolved with about five weeks of oral methylprednisolone dosing prescribed at onset of symptoms...Lower level during clinical episode may be due to use of oral steroid medication. The cytokine elevation may provide clues regarding the pathophysiology of this unusual neurological disorder."

Journal • CNS Disorders • Inflammation • Migraine • Ocular Inflammation • Ophthalmology • Pain • Rare Diseases • IL6

GNT-016-MDYF: A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. The study will start with finding the proper treatment dose (part 1). After that, a comparative study versus placebo will start to assess the safety and the effectiveness of the proper dose of this therapy (part 2). In the end, a follow up... (clinicaltrialsregister.eu) - P1/2 | N=61 | Recruiting | Sponsor: Genethon | N=40 ➔ 61

Enrollment change • Duchenne Muscular Dystrophy • Gene Therapies • Genetic Disorders • Muscular Dystrophy

GNT-016-MDYF: A clinical study in 3 parts with a microdystrophin (called GNT0004), a new gene therapy in boys with Duchenne disease who can still walk. The study will start with finding the proper treatment dose (part 1). After that, a comparative study versus placebo will start to assess the safety and the effectiveness of the proper dose of this therapy (part 2). In the end, a follow up... (clinicaltrialsregister.eu) - P1/2 | N=61 | Recruiting | Sponsor: Genethon

New P1/2 trial • Duchenne Muscular Dystrophy • Gene Therapies • Genetic Disorders • Muscular Dystrophy

Medrol Dosepak for Outpatient Total Knee Arthroplasty (clinicaltrials.gov) - P4 | N=420 | Recruiting | Sponsor: Rush University Medical Center | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: May 2026 ➔ May 2027

Trial completion date • Trial primary completion date • Orthopedics

IgG4-related autoimmune pancreatitis mimicking pancreatic carcinoma: a case report. (PubMed, Front Med (Lausanne)) - "The patient was started on oral methylprednisolone (32 mg/day) and pancreatic enzyme supplements. Over 1 year of follow-up, her serum IgG4 level normalized to 489 μg/mL, CA19-9 returned to 16 U/mL, and serial MRI examinations demonstrated marked resolution of the pancreatic head/neck mass and improvement of the biliary stricture. This case underscores the clinical importance of including IgG4-AIP in the differential diagnosis of pancreatic masses, particularly when serologic or imaging features are equivocal, to prevent unnecessary surgical intervention."

Journal • Immunology • Oncology • Pain • Pancreatic Cancer • Pancreatitis • Solid Tumor • CA 19-9

Constrictive-effusive pericarditis as presenting feature of IgG4-related disease (IgG4-RD): a case report. (PubMed, J Med Case Rep) - "This case highlights difficulty in diagnosing and treating IgG4-RD. His initial IgG4 serum level was normal to only mildly elevated. Definitive diagnosis was via tissue biopsy which required open heart surgery to access. Prior to the diagnosis, he was treated with methylprednisolone which led to severely elevated glucose levels. Oral steroids could not stop the progression of constrictive pericarditis. Pericardiectomy and subsequent treatment with rituximab led to continued remission."

Journal • Cardiovascular • Fibrosis • Immunology • Infectious Disease • Inflammation • Pancreatitis • Respiratory Diseases

Methylone regulates fear memory and amygdala activity: a potential treatment for posttraumatic stress disorder? (CINP 2026) - "These findings suggest that methylone modulates fear memories through its action on the BLA. This preclinical study offers a knowledge base and critical insights into the potential future application of methylone for PTSD treatment."

CNS Disorders • Depression • Mood Disorders • Post-traumatic Stress Disorder • FOS

Aberrant signature methylone by DNMT1 hot spot mutation in hereditary sensory and autonomic neuropathy 1E (CINP 2026) - "HSAN1E is the neurodegenerative disease caused by DNMT1 mutations. The role of DNMT1 is also the only essential methyltransferase to ensure the fidelity of epigenetic inheritance. WBGS study reveals a signature pattern of methylation alteration in this affects neuronal degeneration, characterized by a prevalent hypomethylation in intergenic regions."

Alzheimer's Disease • CNS Disorders • Dementia • DNMT1 • DNMT3A

Case Report: Chronic eosinophilic pneumonia with acute-like presentation and diagnostic challenges. (PubMed, Front Med (Lausanne)) - "Oral methylprednisolone (16 mg/day) was administered for approximately 8-10 weeks, followed by gradual tapering to 8 mg/day, resulting in marked clinical and radiological improvement...An exploratory attenuation-based aeration analysis suggested regional hyperaeration in areas previously affected by consolidation, although its clinical significance remains uncertain. This case illustrates the diagnostic complexity of CEP when acute-like clinical features, atypical imaging findings, and discordant bronchoalveolar lavage results coexist and highlights the importance of integrating clinical, imaging, microbiologic and histopathological data to establish the diagnosis."

Journal • Chronic Cough • Cough • Eosinophilia • Infectious Disease • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases

IgA Vasculitis With Renal Involvement Induced by Disseminated BCG Infection After Intravesical BCG Instillation (ERA 2026) - "He received fosfomycin for 5 days and levofloxacin for 6 days without improvement...Empirical piperacillin–tazobactam was started, then changed to isoniazid, rifampicin, ethambutol and levofloxacin for presumed disseminated BCG infection ("BCGitis")...Oral methylprednisolone was given according to the TESTING protocol...This case links disseminated BCG infection to biopsy ‑ proven IgA vasculitis in a patient with prior cutaneous IgA vasculitis, suggesting BCG as a potent trigger for systemic IgA ‑ mediated disease. It highlights a diagnostic challenge in distinguishing infection ‑ related injury from primary glomerulonephritis and illustrates that combined antimycobacterial therapy and corticosteroids can lead to meaningful renal recovery."

Acute Kidney Injury • Bladder Cancer • Genito-urinary Cancer • Glomerulonephritis • Hypertension • Infectious Disease • Inflammatory Arthritis • Lupus Nephritis • Nephrology • Renal Disease • Respiratory Diseases • Rheumatoid Arthritis • Solid Tumor • Tuberculosis • Vasculitis

Stapokibart (anti–IL-4Rα monoclonal antibody) across type 2 inflammatory diseases in routine practice: a three-case series of severe atopic dermatitis, chronic urticaria with rhinosinusitis, and immune-related bullous pemphigoid (EAACI 2026) - " Case 1 (27 years, AD) had persistent disease despite dupilumab, abrocitinib and upadacitinib...Case 3 (70 years, BP) received stapokibart with oral methylprednisolone taper; BP180 decreased from 191.5 RU/mL at baseline to 29.6 on day 8, 20.5 on day 22, and 14.9 on day 36 with clinical improvement; no new safety signals were reported. In this three-case series, stapokibart was associated with improvement across distinct type 2 inflammatory phenotypes, including difficult-to-treat AD and therapy-associated BP with a parallel serological response. Prospective studies are needed to define predictors of response, positioning with concomitant therapies and safety in complex comorbid settings."

Clinical • Late-breaking abstract • Atopic Dermatitis • Dermatitis • Immunology • Inflammation

MOG-IgG-associated encephalitis and bronchopneumonia in a child with negative infection screening: a case report and literature review. (PubMed, Front Pediatr) - "Oral methylprednisolone (32 mg/day), calcitriol soft capsules (1 capsule/day), and calcium carbonate D3 tablets (1 tablet/day) were prescribed after discharge, with a follow-up examination 1 week later...This report offers new insights into atypical MOGAD and a reference for MOGAD diagnosis and treatment in children. It highlights the importance of conducting MOG-IgG tests in children with encephalitis and bronchopneumonia despite negative infection screening."

Journal • CNS Disorders • Infectious Disease • Pain • Pneumonia • Respiratory Diseases • Solid Tumor

EASE-NMO: Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder (clinicaltrials.gov) - P2 | N=110 | Active, not recruiting | Sponsor: Tianjin Medical University General Hospital | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Sep 2026 | Trial primary completion date: Aug 2026 ➔ Apr 2026

Enrollment closed • Trial completion date • Trial primary completion date • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases